AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38159652
Drug: Anticonvulsants
RxNorm normalized name: ANTICONVULSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticonvulsants
Trial: 32545143
Drug: Moringa leaf
RxNorm normalized name: Moringa oleifera leaf oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moringa leaf extract and iron capsules
Trial: 32545143
Drug: Iron capsules
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron capsules
Trial: 39506661
Drug: Treatment-as-usual group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual group
Trial: 33997885
Drug: Dexamethasone suppression
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone suppression test (DST) with method-specific cortisol cutoff of 2.4 µg/dL
Trial: 33997885
Drug: Dexamethasone <1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone <1.8 ng/mL in AI-ACS samples
Trial: 35078116
Drug: Perampanel (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel (maximum dose: 12 mg/day)
Trial: 35482347
Drug: Experimental agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental agent (cancer drug)
Trial: 38620092
Drug: Targeted drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted drugs
Trial: 35482347
Drug: Immunotherapy drugs
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy drugs
Trial: 35482347
Drug: Non-immunotherapy-targeted drugs
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-immunotherapy-targeted drugs
Trial: 33325793
Drug: Intravitreal dexamethasone
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal dexamethasone (IVD) implant
Trial: 33325793
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no IVD implant)
Trial: 33091102
Drug: Monthly audits
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly audits of all ADC pockets
Trial: 33091102
Drug: Monthly audits
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly audits of matrix (open pocket) drawers only
Trial: 33091102
Drug: Monthly audits
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly audits of unassigned pockets only
Trial: 36459910
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PTB) applied at pain points (G2) with a dose of 4 J and 6 J.
Trial: 36459910
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PTB) applied at pre-established points (G1) with a dose of 4 J and 6 J.
Trial: 33538902
Drug: Increased blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased blood pressure to 150 mmHg for 5 min using norepinephrine pump (0.05 μg/kg/min initial dose) after specimen extraction during ESD
Trial: 34312043
Drug: SCT+HE (Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCT+HE (Standard Conservative Therapy plus Home Exercise)
Trial: 34312043
Drug: SCT (Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCT (Standard Conservative Therapy)
Trial: 32603281
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive surgical therapies (MISTs)
Trial: 32603281
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (drugs)
Trial: 35189848
Drug: Group self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group self-management support (10 weekly 2.5-hour group web-based sessions with 10-15 patients and two trained facilitators)
Trial: 36470757
Drug: Social media-based
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social media-based drama therapy
Trial: 36470757
Drug: Social media-based
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social media-based art therapy
Trial: 36470757
Drug: Social media-based
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social media-based music therapy
Trial: 35393218
Drug: Full 90-minute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full 90-minute HBOT dose in a pressurized chamber with 100% oxygen at 2.0 ATA
Trial: 35393218
Drug: Full 90-minute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full 90-minute HBOT dose
Trial: 33891380
Drug: Bimekizumab (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab (320 mg subcutaneously every 4 weeks)
Trial: 33891380
Drug: Secukinumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab (300 mg subcutaneously weekly to week 4, then every 4 weeks)
Trial: 34172470
Drug: Continuing mepolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing mepolizumab 100 mg every 4 weeks
Trial: 34247980
Drug: Conventional fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fluid therapy (Control)
Trial: 34909045
Drug: L-carnitine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (1.5 g daily for six days)
Trial: 33765054
Drug: Adenosine (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (18 mg intravenous bolus)
Trial: 34166000
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (n = 203)
Trial: 35361691
Drug: Two-dose vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose vaccination
Trial: 33010241
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg
Trial: 35430238
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ulipristal acetate daily
Trial: 35430238
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ulipristal acetate daily
Trial: 35430238
Drug: Cyclic regimen
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic regimen of 5 mg ulipristal acetate for 24 days followed by four placebo days
Trial: 35430238
Drug: All ulipristal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All ulipristal acetate treatments
Trial: 35430238
Drug: Endometrial biopsies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial biopsies during treatment
Trial: 35430238
Drug: Cyclic regimen
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic regimen of 5 mg ulipristal acetate
Trial: 34792161
Drug: Higher dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dialysate sodium concentration (142 mmol/L)
Trial: 34792161
Drug: Lower dialysate
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dialysate sodium concentration (138 mmol/L)
Trial: 32562632
Drug: Late-parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late-parenteral nutrition
Trial: 32562632
Drug: Early-parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-parenteral nutrition
Trial: 35112386
Drug: Essential Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential Health Care Programme (EHCP) - daily toothbrushing with fluoride toothpaste
Trial: 35112386
Drug: EHCP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHCP + Fluoride - weekly application of high-concentrated fluoride gel
Trial: 35112386
Drug: EHCP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHCP + OUT - twice-yearly access to on-demand urgent oral treatment
Trial: 35112386
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - standard school-based oral health education
Trial: 32073559
Drug: Gastroftal eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastroftal eye drops and tablets (Group B)
Trial: 36481516
Drug: 3P intervention
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3P intervention (combination of imaginal retraining and decoupling)
Trial: 34479958
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human parathyroid hormone (1-84)
Trial: 36090002
Drug: Jintiange capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jintiange capsules (1.2 g each time, 3 times per day) and alfacalcidol (0.25 μg/d)
Trial: 36090002
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (element calcium 0.3 g, twice a day) and alfacalcidol (0.25 μg/d)
Trial: 35010445
Drug: e-mail-delivered cognitive
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: e-mail-delivered cognitive behavioral therapy for insomnia (CBT-I) (REFRESH)
Trial: 34894470
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg terazosin (TZ)
Trial: 34883313
Drug: Disease-modifying treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-modifying treatment available
Trial: 36456480
Drug: Ergometrine combined
RxNorm normalized name: Ergometrine
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergometrine combined with oxytocin (intra-myometrial injection following oxytocin intravenously)
Trial: 36456480
Drug: Oxytocin alone
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin alone (intra-myometrial injection following oxytocin intravenously)
Trial: 36420866
Drug: Honey (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey (1 g kg-1 day-1) and Nigella sativa seeds (80 mg kg-1 day-1)
Trial: 32481277
Drug: Shexiang Tongxin
RxNorm normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shexiang Tongxin Dropping Pills (STDP) combined with routine medicine
Trial: 32481277
Drug: Nicorandil combined
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil combined with routine medicine
Trial: 32481277
Drug: STDP combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STDP combined with routine medicine
Trial: 33090380
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 12 months
Trial: 32049331
Drug: Iron isomaltoside
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron isomaltoside 1000/ferric derisomaltose (IIM) - single dose of 1000 mg IV
Trial: 32049331
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (IS) - administered as 200 mg IV injections up to five times within a 2-week period
Trial: 34923901
Drug: Oral fecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fecal microbiota transplantation (FMT) capsules for 12 weeks (A3)
Trial: 34923901
Drug: Oral empty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral empty capsules for 12 weeks (B3)
Trial: 35356935
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus antihypertensive drugs
Trial: 32045259
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs only (Control)
Trial: 35714267
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to active treatment from sham-control
Trial: 33203003
Drug: Isoflavone supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone supplementation (100 mg/day) and exercise
Trial: 35815739
Drug: omega-3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 PUFA supplementation (1020 mg daily for 12 weeks)
Trial: 33513026
Drug: Elacestrant 400
RxNorm normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elacestrant 400 mg orally once daily
Trial: 35584336
Drug: Standard-of-care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SOC) endocrine monotherapy
Trial: 36401521
Drug: Lanolin treatment
RxNorm normalized name: Lanolin
DrugBank: Lanolin (DB11112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanolin treatment
Trial: 36401521
Drug: Human milk
RxNorm normalized name: HUMAN MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human milk treatment
Trial: 35367282
Drug: Seladelpar 2
RxNorm normalized name: Seladelpar
DrugBank: Seladelpar (DB12390)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seladelpar 2 mg/day
Trial: 35367282
Drug: Seladelpar 5
RxNorm normalized name: Seladelpar
DrugBank: Seladelpar (DB12390)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seladelpar 5 mg/day
Trial: 35367282
Drug: Seladelpar 10
RxNorm normalized name: seladelpar 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seladelpar 10 mg/day
Trial: 35367282
Drug: Seladelpar 5
RxNorm normalized name: Seladelpar
DrugBank: Seladelpar (DB12390)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seladelpar 5 mg/day and 10 mg/day
Trial: 32183815
Drug: Park Prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Park Prescription Intervention (PPI): Face-to-face Park Prescription + invitation to weekly exercise sessions in parks
Trial: 34046921
Drug: STR-324 (0.004-11.475
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STR-324 (0.004-11.475 mg h-1)
Trial: 34046921
Drug: STR-324 (1.25-11.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STR-324 (1.25-11.25 mg h-1)
Trial: 36218094
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of carboprost combined with oxytocin (20IU oxytocin and small pot drip of 10IU oxytocin after delivery)
Trial: 36218094
Drug: 1mg of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg of carboprost when the fetal head came out and then intramuscular injection of 20IU oxytocin
Trial: 33983840
Drug: Oropharyngeal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal administration of colostrum during mechanical ventilation
Trial: 32668036
Drug: Endodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic treatment with post-installation at the first visit (group 1)
Trial: 32668036
Drug: Endodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic treatment with post-installation at the second visit (group 2)
Trial: 35850080
Drug: Olive Oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive Oil (OO) 3 g/day
Trial: 35850080
Drug: Fish Oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish Oil (FO) 3 g/day
Trial: 38341187
Drug: 17DD vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17DD vaccine
Trial: 39406403
Drug: Bimekizumab 160
RxNorm normalized name: Bimekizumab 160 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab 160 mg every 4 weeks
Trial: 32854568
Drug: Roflumilast 250
RxNorm normalized name: ROFLUMILAST 250MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 250 µg
Trial: 37792369
Drug: Uncoated aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uncoated aspirin
Trial: 35977951
Drug: tinnitus retraining
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tinnitus retraining therapy
Trial: 35977951
Drug: auditory discrimination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: auditory discrimination therapy
Trial: 35977951
Drug: binaural beats
FDA approved: no
EMA approved: no
PMDA approved: no
Description: binaural beats therapy
Trial: 32358379
Drug: Chinese patent
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese patent medicine
Trial: 39282906
Drug: Pembrolizumab-chemotherapy group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab-chemotherapy group
Trial: 39282906
Drug: Placebo-chemotherapy group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-chemotherapy group
Trial: 33251650
Drug: Topical sirolimus
RxNorm normalized name: sirolimus Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sirolimus 0.2% cream plus Pulsed Dye Laser (PDL)
Trial: 36892190
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg)
Trial: 32227216
Drug: Topiramate (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (maximum dosage of 300 mg for 13 weeks)
Trial: 32452118
Drug: Isorhamnetin administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isorhamnetin administered orally for 21 consecutive days
Trial: 32452118
Drug: Sildenafil administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil administered orally for 21 consecutive days
Trial: 32945055
Drug: Intermittent theta
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent theta burst stimulation (iTBS), 1800 pulses/session, ten daily sessions
Trial: 32307654
Drug: Immunotherapy (immune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (immune checkpoint inhibitors)
Trial: 33917165
Drug: Green leafy
RxNorm normalized name: Green tea leaf
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green leafy vegetables (GLV) intervention, 1 cooked cup equivalent daily for 4 weeks
Trial: 34475255
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment for acute ischemic stroke (AIS)
Trial: 39423145
Drug: Deucravacitinib 6
RxNorm normalized name: deucravacitinib 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib 6 mg
Trial: 36098968
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids, 1 g/d
Trial: 35691183
Drug: Arginine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arginine (10 g)
Trial: 34555839
Drug: IV cetirizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV cetirizine 10 mg
Trial: 34555839
Drug: IV diphenhydramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV diphenhydramine 50 mg
Trial: 35854360
Drug: Oral fluoroquinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluoroquinolone or trimethoprim-sulfamethoxazole
Trial: 37858867
Drug: Intravenous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous therapy
Trial: 32334592
Drug: Twice-daily exenatide
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily exenatide
Trial: 32334592
Drug: Insulin (aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (aspartate 70/30)
Trial: 33272368
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg once daily for 12 weeks
Trial: 35348111
Drug: SB12 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB12 (300 mg dose via intravenous infusion)
Trial: 35348111
Drug: Eculizumab (RP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (RP, 300 mg dose via intravenous infusion)
Trial: 35040072
Drug: Neurodevelopmental Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodevelopmental Therapy (NDT)
Trial: 32948057
Drug: multi-DNA damage
RxNorm normalized name: Head & Shoulders Damage Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multi-DNA damage response interference (mDDRi) as maintenance therapy
Trial: 32948057
Drug: FOLFIRINOX treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX treatment
Trial: 36599736
Drug: HEV 239
RxNorm normalized name: Immunoglobulin G1-lambda2, anti-[Homo sapiens IL33 (interleukin 33, DVS27, NF-HEV, IL1F11)], monoclonal antibody; gamma1 heavy chain (1-456) [VH (Homo sapiens IGHV3-23*01 (93.9%) -(IGHD) -IGHJ4*01 (85.7%) L123>M (121)) CDR-IMGT [8.8.19] (26-33.51-58.97-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEV 239 vaccine